|
|
| Welcome
to LymphomaLinks,
your monthly source of lymphoma news, research
updates, clinical trials and events sponsored by
The Leukemia & Lymphoma Society (LLS). For
even more information, regularly visit
LLS's Patient
Services and Disease
Information Web
sections. | |
 |
|
Latest Lymphoma
News
Non-Hodgkin
Patients Living Longer:
Study
Improved
treatments for non-Hodgkin's lymphoma helped
patients live longer in the United States. In
particular, the
targeted drug Rituxan®, in
combination with chemotherapy, has helped
younger patients with non-Hodgkin
lymphoma. ::
READ MORE
NEWS::
| |
|
LLS
Features
::READ MORE::
.....................................................................................................................................
Research
Roundup
::READ MORE::
.....................................................................................................................................
IRC Question of
the Month
:: READ
MORE::
| |
|
Inspirational
Stories
 Learn how individuals touched
by blood cancer cope. LLS's LifeMosaic Web feature offers
hundreds of inspiring stories by patients and families. Read
them or submit your own.
|
Here to
Help
For
even more information, regularly visit the LLS
Web site,
www.LLS.org
,
where many of our education programs are
archived free of charge for convenient access
24/7.
If you haven't found what you're
looking for in LymphomaLinks , please
call our Information Resource Center (IRC) to
speak with trained information specialists. IRC
staff are available Monday through Friday, 9
a.m. to 6 p.m. ET, toll free at (800) 955-4572;
email
infocenter@lls.org
;
or click the "Live Patient Help" button on the
www.LLS.org homepage.
| |
|
|
Commentary from the
Society
Certain
cancer drugs can cause heart problems.
Learn what scientists are doing to help
patients. ::READ MORE::
Clinical
Trials
We
invite you to use our Clinical
Trial Service, a free and confidential
service that can help you find clinical trials
that meet your
needs.
You may also want to visit the
National Cancer Institute's Cancer
Trials Support Unit, providing resources and
information on phase III cancer treatment trials
supported by the National Cancer
Institute
. ::SELECTED TRIALS::
Newsfeeds &
Podcasts
Now you can get
RSS Feeds and Podcasts from LLS.
::CLICK HERE TO SIGN
UP::
Free
eNewsletters
Free LLS
eNewsletters deliver the latest information on
research and treatment options, patient services
programs and fundraising events.
:: CLICK HERE TO SIGN
UP::
| | | |
| 
| | | |
|
|
|
Progress
in Mantle Cell Lymphoma: Update from the
Experts
This free
teleconference will take place
Wednesday, April 30, noon - 2 p.m., and will
feature John Leonard, M.D., associate professor
of medicine, Weill Medical College of Cornell
University, clinical director, New York-Cornell
Center for Lymphoma; and Brad Kahl,
M.D., associate professor
and director, Lymphoma Service, Department
of Medicine, Section of Hematology, University
of Wisconsin School of Medicine. Register
online.
New
Podcasts
Too busy to participate in a
live LLS telephone education program? Listen to
an archived version by adding our podcast
feeds to your computer. Podcast audio files
are sent to you automatically and feature
leading medical experts discussing a wide range
of blood cancer-related topics. There are many
podcasts to choose from, including seven
new feeds dedicated to recent
teleconferences. Sign up today. It's easy.
LLS
Blog
Check out
the new LLS blog for patients and
caregivers. The blog features top blood
cancer-related news and provide
personal stories from the folks
who are most affected by blood
cancers - patients and the ones who care for
them. The blog is completely interactive; you
can respond to people's posts. And while you're
there, visit our Cancer Centers
section.
Take Action
As survival rates increase for the
estimated 20,000 children under the age of 21
diagnosed with cancer in the United States each
year, so do complications resulting from their
treatment. U.S. Reps. Hilda L. Solis and Mary
Bono Mack have introduced legislation to enhance
the study and treatment of these "late effects"
of treatment for childhood cancer survivors.
Please, urge your member of Congress to
co-sponsor H.R. 4450
today.
Co-Pay
Assistance Program
Patients who have difficulty paying
for - or simply cannot afford -
their health insurance premiums or prescription
drug co-pays can now apply for
assistance from
LLS.
Learn
the many ways you can help
advance the LLS mission, including making a
donation. Find
out more about our other
eNewsletters.
> Back to the
top
| |
|
Phase I trial and pharmacokinetic
study of bevacizumab in pediatric patients with
refractory solid tumors: Children's
Oncology Group Study ::READ MORE::
Six versus eight cycles of
bi-weekly CHOP-14 with or without rituximab in
elderly patients with aggressive CD20+ B-cell
lymphomas: a randomized, controlled trial
(RICOVER-60) ::READ MORE::
Fludarabine-melphalan as a
preparative regimen for reduced-intensity
conditioning allogeneic stem cell
transplantation in relapsed and refractory
Hodgkin lymphoma: the updated M.D. Anderson
Cancer Center experience ::READ MORE::
Late computed tomography
scan response improvement and gallium
scintigraphy evaluation as on-treatment
prognostic parameters to tailor treatment
intensity in patients with Hodgkin lymphoma: a
prospective Phase II study ::READ MORE::
Results of a Phase III
clinical trial: CHOP versus CMED in peripheral
T-cell lymphoma unspecified ::READ MORE::
> Back
to the
top
| |
 We
invite you to use our Clinical
Trial Service, a free and confidential
service that can help you find clinical trials
that meet your needs. You may also want to visit
the National Cancer Institute's Cancer
Trials Support Unit , providing resources
and information on phase III cancer treatment
trials supported by the National Cancer
Institute.
Selected
Trials
Phase III: Rituximab in Treating
Patients with Low Tumor Burden Indolent
Non-Hodgkin Lymphoma ::READ MORE::
Vaccine Therapy and GM-CSF in
Treating Patients with CNS Lymphoma ::READ MORE::
Peripheral Stem Transplantation in
Treating Patients with Refractory or Relapsed
Lymphoma ::READ MORE::
Phase II: MGCD0103 Given
Three Times Weekly in Patients with Relapsed and
Refractory Lymphoma ::READ MORE::
Phase III: Comparing Inotuzumab
Ozogamicin in Combination with Rituximab versus
Defined Investigator's Choice in Follicular
Non-Hodgkin Lymphoma ::READ MORE::
> Back to the
top
| |
IRC
Question of the Month: Integrative
Medicine
| 
Q: I've heard about using
integrative medicine as part of cancer
treatment. Can you tell me what this
is?
A: Integrative medicine
supports the use of some complementary and
alternative medicine (CAM) therapies - those
that have been found to be safe and effective -
in addition to conventional cancer therapies,
such as drug therapy, radiation therapy and
immunotherapy.
CAM therapies include support groups,
therapeutic massage, acupuncture, meditation,
yoga, art therapy and music therapy, among
others. There is no scientific evidence to date
that any CAM therapies will slow cancer
progression. However, some cancer patients say
that an integrative medicine approach helps
them to cope with their disease and
treatment, to feel better and to have a sense of
control over their health.
Studies are ongoing to evaluate CAM therapies
and to determine those that are safe and
effective for people living with leukemia,
lymphoma, myeloma, myelodysplastic
syndromes and other diseases. It is
important for patients to talk openly with their
treatment teams about any CAM therapies they are
currently using or considering using.
LLS has a fact sheet about integrative
medicine with information about CAM therapies,
including questions to ask your physician and
how to locate licensed IM and CAM providers. Click
here to read a copy online.
As always the Information Resource Center
(IRC) is here to help. To speak with an IRC
specialist, Monday through Friday, 9 a.m.
to 6 p.m. ET, please call (800)
955-4572.
| | | | | | | |
